Aimmune Therapeutics announced the approval of PALFORZIA™ by the U.S. Food and Drug Administration (FDA), making it the first approved treatment for patients with peanut allergy.
PALFORZIA is a biologic drug for peanut oral immunotherapy (OIT) for children 4-17 years of age. With OIT, small amounts of the allergen are given by mouth in gradually increasing doses until the patient is able to eat a certain amount of it without having a reaction so long as they are on this treatment.
Although PALFORZIA is available in the U.S. only right now, we want to hear your thoughts on this news. Tell us what you think below: